Track topics on Twitter Track topics that are important to you
RATIONALE: EMD 121974 may stop the growth of Kaposi's sarcoma by stopping blood flow to the tumor.
OBJECTIVES: I. Determine the safety and toxicity of EMD 121974 in patients with HIV related Kaposi's sarcoma. II. Determine the antiangiogenic activity of this drug in these patients. III. Determine the antitumor activity of this drug in these patients. IV. Determine the effect of this drug on CD4 and CD8 cell counts and percentages, and on HIV viral load in these patients. V. Determine the pharmacokinetics of this drug in these patients.
OUTLINE: This is a dose escalation study. Patients receive EMD 121974 IV twice a week for four weeks. Courses repeat every 4 weeks in the absence of disease progression. Cohorts of 3-6 patients receive escalating doses of EMD 121974 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicities. Patients are followed for at least 1 month.
PROJECTED ACCRUAL: A total of 18-30 patients will be accrued for this study within 1 year.
Primary Purpose: Treatment
University of California San Diego Cancer Center
National Cancer Institute (NCI)
Published on BioPortfolio: 2014-08-27T03:57:25-0400
RATIONALE: Cilengitide may stop the growth of prostate cancer by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well cilengitide works in treating patients...
RATIONALE: Cilengitide may stop the growth of glioblastoma multiforme by blocking blood flow to the tumor. Giving cilengitide before and after surgery may be an effective treatment for gli...
RATIONALE: Cilengitide may stop the growth of prostate cancer by blocking blood flow to the tumor. PURPOSE: This randomized phase II trial is studying how well cilengitide works in treati...
This clinical trial is studying how well giving cilengitide together with sunitinib malate works in treating patients with advanced solid tumors or glioblastoma multiforme. Cilengitide and...
RATIONALE: Cediranib maleate and cilengitide may stop the growth of tumor cells by blocking blood flow to the tumor. Giving cediranib maleate together with cilengitide may kill more tumor ...
Targeting of αVβ3 and αVβ5 integrins by cilengitide may reduce growth of solid tumors including head and neck squamous cell carcinoma (HNSCC). Preclinical investigations suggest increased activity...
Options for preserving fertility in children and adolescents with cancer depend on patient age, the available time frame, and the treatment regimen. Ovarian stimulation with mature oocyte preservation...
Fibrosis is a common feature of several chronic diseases, and is characterized by exacerbated accumulation of extracellular matrix (ECM). Understanding the cellular and molecular mechanisms involved i...
Hepatocellular carcinoma (HCC) is one of the most common cancers and it usually develops from a background of liver fibrosis or inflammation. The crosstalk between tumor cells and stromal cells plays ...
An experimental sarcoma of mice.
An experimental sarcoma of mice.
An experimental sarcoma of rats.
Experimentally induced neoplasms of CONNECTIVE TISSUE in animals to provide a model for studying human SARCOMA.
A family of transforming proteins isolated from retroviruses such as MOUSE SARCOMA VIRUSES. They are viral-derived members of the raf-kinase family of serine-theonine kinases.
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...
AIDS and HIV
AIDS; Acquired Immune Deficiency Syndrome. HIV; Human Immunodeficiency Virus HIV infection causes AIDS. HIV infection also causes the production of anti-HIV antibodies, which forms the test for HIV in patients. People who have the HIV antibodies are ...